Loading...
•
Dec 31, 2020
Aytu BioScience Q2 2021 Earnings Report
Reported record fiscal Q2 2021 net revenue with increased consumer health revenue.
Key Takeaways
Aytu BioScience reported a record fiscal Q2 2021 net revenue of $15.1 million, a 377% increase year-over-year. The Consumer Health revenue reached an all-time high of $7.9 million, and the company ended the quarter with $62.3 million in cash, cash equivalents, and restricted cash.
Net revenue reached an all-time high of $15.1 million, compared to $3.2 million for Q2 2020.
Consumer Health division net revenue was an all-time high of $7.9 million.
Rx division net revenue was $7.2 million.
Ended the quarter with $62.3 million in cash, cash equivalents and restricted cash.
Forward Guidance
The merger accelerates the company’s transformation, and, upon closing, we expect to begin realizing estimated annualized cost synergies of $15 million in FY 2022.
Positive Outlook
- Expected synergies of $15 million in FY 2022.
- Adds Neos' established, multi-brand ADHD portfolio.
- Enhances footprint in pediatrics.
- Expands Aytu’s presence in adjacent specialty care segments.
- Creates the opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...